SV Life Sciences

Portfolio

SV Life Sciences currently advises or manages five funds with capital commitments of approximately $2.0 billion which primarily invest amounts of between $1m and $40m in North America and Europe, but will consider innovative investments in other regions. This part of our website provides a brief summary of each portfolio company with links to their websites where possible.

78 matching investments found

Company	Country	Stage	Sector	Year
Allos Therapeutics	US	Early Stage	Biotechnology Biopharmaceuticals	1998
Allos Therapeutics was developing and commercializing innovative small molecule therapeutics for the treatment of cancer.
Axys Pharmaceuticals	US	Early Stage	Biotechnology Biopharmaceuticals	1994
Axys developed a protease-inhibitor based products for cancer & inflammatory diseases.
Cerebrus	UK	Start Up	Biotechnology Biopharmaceuticals	1995
Cerebrus CNS drug discovery (Acquired by Nigra, which was then bought by Vernalis)
Cytomed	US	Early Stage	Biotechnology Biopharmaceuticals	1997
Cytomed was a leukotriene inhibitors for asthma (Acquired by LeukoSite Inc and then by Millenium).
Geltex Pharmaceuticals	US	Early Stage	Biotechnology Biopharmaceuticals	1998
Geltex developed novel non-absorbed pharmaceuticals. Geltex was acquired by Genzyme Corporation after our exit through public markets.
Incyte Pharmaceuticals	UK	Start Up	Biotechnology Biopharmaceuticals	1996
Functional genomics Acquired by Incyte Pharmaceuticals in September 1999.
Kinetix Pharmaceuticals	US	Start Up	Biotechnology Biopharmaceuticals	1999
Kinase targeted drug discovery. Acquired by Amgen in October 2000.
LeukoSite	US	Start Up	Biotechnology Biopharmaceuticals	1994
LeukoSite was a treatment of Inflammatory diseases and cancer. Acquired by Amgen in October 1999.
Shire Pharmaceuticals	US	Early Stage	Biotechnology Biopharmaceuticals	1994
Ticker: SHP LN Shire Pharmaceuticals - speciality pharma company formed on osteoporosis and Alzheimer's disease.
Strides Arcolab	India	Expansion	Biotechnology Biopharmaceuticals	1997
Strides Arcolab was a manufacturer of generic pharmaceuticals.
Triangle Pharmaceuticals	US	Start Up	Biotechnology Biopharmaceuticals	1995
Triangle Pharmaceuticals was an antiviral and anticancer drug development company. Acquired by Gilead in January 2003.
Vanguard Medica (Vernalis)	UK	Early Stage	Biotechnology Biopharmaceuticals	1995
Vanguard Medica was an antiviral and anticancer drug development company. (Acquired by Vernalis)
Metris Therapeutics	UK	Start Up	Biotechnology Biopharmaceuticals	2000
Metris is a women's healthcare company that is developing drugs for the treatment of chronic gynecological and menstrual conditions.
Micromet	US	Start Up	Biotechnology Biopharmaceuticals	1998
(NASDAQ: MITI) Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer.
Achillion Pharmaceuticals	US	Start Up	Biotechnology Biopharmaceuticals	2000
(NASDAQ: ACHN). Achillion, based in New Haven, CT, is focused on the discovery, development and commercialization of innovative small molecule therapeutics for the treatment and/or prevention of serious infections associated with drug resistant viruses or bacteria.
Aderis Pharmaceuticals	US	Expansion	Biotechnology Biopharmaceuticals	2001
Aderis Pharmaceuticals was a Cardiovascular, renal and neurological disease focused therapeutics focused upon making a significant difference to people living with cardiovascular, renal and neurological diseases.
Affibody	Sweden	Early Stage	Biotechnology Biopharmaceuticals	2001
Affibody is a biotech company that uses unique affinity ligands to develop products for molecular imaging, targeted therapy and biotechnology applications. The lead product is a Her2 affibody for clinical imaging in breast cancer, and its pipeline includes other oncology imaging affibodies. In addition, affibodies are sold as research reagents and for use in protein separations.
Atopix Therapeutics and Oxagen	UK	Early Stage	Biotechnology Biopharmaceuticals	2000
Atopix Therapeutics and Oxagen are related through an investment made in to Atopix in Q1 2012 and an agreement with Oxagen to allow Atopix to continue to develop the technology started by Oxagen. The companies are based in Oxford, UK. The companies are developing drugs targeted at inflammatory and metabolic diseases. www.atopixtherapeutics.co.uk / www.oxagen.co.uk
Auxilium Pharmaceuticals	US	Early Stage	Biotechnology Biopharmaceuticals	2001
Auxilium developed a male hormone replacement therapy.
Celldex/Lorantis	UK	Start Up	Biotechnology Biopharmaceuticals	2000
Celldex merged with the quoted company Avant Immunotherapeutics (ticker:'AVAN') in March 2008. Celldex, formerly a wholly owned subsidiary of Medarex Inc., merged with Lorantis Ltd in 2005. Celldex pursues immunological approaches to the treatment of cancers, infectious disease and immunological disorders.
Cellzome	Germany	Start Up	Biotechnology Biopharmaceuticals	2001
Cellzome is a drug discovery company building a R&D pipeline in chronic diseases by leveraging its unique drug proteomics engine. The business is based in Heidelberg, Germany and Cambridge, UK.
Cognis	Luxembourg	Buyout	Biotechnology Biopharmaceuticals	2001
Cognis is a global supplier of innovative speciality chemicals for the cosmetics, detergents and cleaners industries and nutrional ingredients to the food and healthcare markets.
Eyetech Pharmaceuticals	US	Early Stage	Biotechnology Biopharmaceuticals	2000
Eyetech was bought by OSI Pharmaceuticals after our exit through public markets. Opthalmolological drug development.
Ingenium	Germany	Early Stage	Biotechnology Biopharmaceuticals	2000
Ingenium was a functional genomics and drug development company.
KuDOS Pharmaceuticals	UK	Start Up	Biotechnology Biopharmaceuticals	1999
KuDOS was an oncology drug development company. Acquired by Astra Zeneca in December 2005.
Orchid Chemicals and Pharmaceuticals	India	Expansion	Biotechnology Biopharmaceuticals	1999
Orchid manufactured bulk generic pharmaceuticals.
Quantum Dot	US	Early Stage	Biotechnology Biopharmaceuticals	2000
Quantum Dot developed nanocrystal biological reagents.
Solexa	UK	Start Up	Biotechnology Biopharmaceuticals	2001
Sold to Illumina ILMN. Solexa used ultra high throughput DNA sequencing.
Third Wave Technologies	US	Expansion	Biotechnology Biopharmaceuticals	1999
Third Wave developed products for analysing genetic variations.
Trine Pharmaceuticals	US	Expansion	Biotechnology Biopharmaceuticals	2001
Trine, formerly Essential Therapeutics Inc., in-licenses, develops and plans to commercialize new classes of pharmaceutical products focused on renal, metabolic and GI clinical areas.
Versicor	US	Expansion	Biotechnology Biopharmaceuticals	1999
Versicor was a drug development company for infectious diseases (Changed name to Vicurion Pharmaceuticals in 2003)
Alantos Pharmaceuticals	US	Early Stage	Biotechnology Biopharmaceuticals	2003
Sold to Amgen in June 2007. Alantos was a chemistry-driven company seeking to discover and develop drugs targeted at osteoarthritis and inflammatory processes. The company attempts to fast follow others to reduce risk.
Alba Therapeutics	US	Early Stage	Biotechnology Biopharmaceuticals	2005
Alba based in Baltimore, MD, is focused on the development and commercialization of pharmaceuticals for the treatment of inflammatory and immune mediated diseases. Alba's technology provides the ability to transiently open or close internal barriers such as the intestinal mucosa. Alba is applying its technology to develop treatments for celiac disease and other autoimmune conditions.
Alinea Pharmaceuticals	US	Expansion	Biotechnology Biopharmaceuticals	2005
Dedicated to developing and commercializing pharmaceuticals for the treatment of diabetes and related metabolic disorders.
Archemix	US	Early Stage	Biotechnology Biopharmaceuticals	2002
Archemix, based in Cambridge, MA, is developing nucleic acid aptamers for therapeutic indications, building on a broad IP portfolio acquired from Gilead/Nexstar.
Avera Pharmaceuticals	US	Early Stage	Biotechnology Biopharmaceuticals	2004
Avera is based in San Diego, CA and focused on the development of small molecule drugs for the treatment of diseases affecting the central nervous system (CNS). Key programs are Alzheimer's disease, schizophrenia associated cognition deficits, IBS, and OAB, and developing an ultra-short acting anaesthesia compound.
Celldex/Lorantis	UK	Seed	Biotechnology Biopharmaceuticals	2003
Celldex merged with the quoted company Avant Immunotherapeutics (ticker:'AVAN') in March 2008. Celldex, formerly a wholly owned subsidiary of Medarex Inc., merged with Lorantis Ltd in 2005. Celldex pursues immunological approaches to the treatment of cancers, infectious disease and immunological disorders.
Dynogen Pharmaceuticals	US	Early Stage	Biotechnology Biopharmaceuticals	2004
Dynogen is a neuroscience-based company focused on genito-urinary (GU) and gastro-intestinal (GI) disorders. The company is using its knowledge of neurology and GU/GI disorders to build a pipeline of clinical candidates.
ESBATech	Switzerland	Early Stage	Biotechnology Biopharmaceuticals	2006
Sold to Alcan in September 2009. ESBATech is a preclinical stage drug discovery company that intends to refocus the business to build a world class Ophthalmology company on the back of an attractive, proprietary antibody fragment platform which can deliver uniquely stable, soluble and monomeric fragments and compelling data on penetration of these fragments into the eye following topical treatment.
GlycoFi	US	Start Up	Biotechnology Biopharmaceuticals	2002
Sold to Merck in May 2006. GlycoFi was a production and engineering of therapeutics proteins.
Ikano Therapeutics	US	Early Stage	Biotechnology Biopharmaceuticals	2006
ITI is a specialty pharmaceutical company focused on developing innovative, nasally delivered pharmaceutical products with a particular focus on drugs treating pain and CNS-related disorders for which there is proven, unmet patient need.
Neurotech	US	Early Stage	Biotechnology Biopharmaceuticals	2006
Neurotech based in Lincoln, RI, has developed an encapsulated cell therapy for the delivery of therapeutic proteins in retinal diseases. The first product is ciliary neurothrophic factor (CNTF) for retinitis pigmentosa and age-related macular degeneration (geographic atrophy).
PowderMed	UK	Early Stage	Biotechnology Biopharmaceuticals	2004
Sold to Pfizer in October 2006. PowderMed developed therapeutic DNA vaccines in the areas of chronic viral diseases and cancer.
Rinat Neuroscience	US	Early Stage	Biotechnology Biopharmaceuticals	2003
Sold to Pfizer in April 2006. Rinat developed proteins for the treatment of diseases and disorders of the nervous system.
Sapphire Therapeutics	US	Early Stage	Biotechnology Biopharmaceuticals	2004
Acquired by Helsinn in February 2009. Helsinn is developing small molecule drugs based on the biology of ghrelin,a gut peptide known to stimulate appetite. The lead compound is in Ph II for cancer cachexia; a second compound has completed an initial clinical study and is moving toward Ph II for post-operative ileus. Additional indications are being explored for follow-on compounds. Formerly known as Rejuvenon.
Delenex Therapeutics	Switzerland	Early Stage	Biotechnology Biopharmaceuticals	2009
Delenex is a spin out from ESBATech, an investment that was divested in 2009. The business focuses on research and development in its antibody fragments for topical delivery.
Mpex Pharmaceuticals	US	Early Stage	Biotechnology Biopharmaceuticals	2005
Mpex based in San Diego, CA, is focused on the discovery and development of new-antibacterial drugs that meet the growing clinical need created by multi-drug resistant bacteria. Mpex has identified several approaches to increase the effectiveness of existing antibiotics and decrease the incidence of drug resistance to these antibiotics. Mpex's first product will be an inhaled antibiotic for serious lung infections.
Lux Biosciences	US	Seed	Biotechnology Biopharmaceuticals	2006
Lux is developing drugs for ophthalmic diseases. Their lead product is LX211, an oral drug for the treatment of uveitis.
Sutro Biopharma, Inc	US	Early Stage	Biotechnology Biopharmaceuticals	2006
Sutro Biopharma's mission is to enable the production of low-cost, high quality rapidly developed protein pharmaceuticals and innovative vaccines that cannot be manufactured by existing technologies. Previously known as Fundamental Applied Biology's (FAB).
Adimab	US	Start Up	Biotechnology Biopharmaceuticals	2007
Adimab, LLC has developed a fully integrated platform for antibody discovery and manufacturing which offers customers/ acquirers a very rapid, 2-3 month path from target to optimized antibody while eliminating most, if not all, third party royalties.
Affinium Pharmaceuticals	US	Early Stage	Biotechnology Biopharmaceuticals	2007
Affinium Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines stemming from the bacterial fatty acid synthesis pathway.
Allocure	US	Early Stage	Biotechnology Biopharmaceuticals	2008
Allocure is a biotechnology company at the forefront of innovative cell therapies for the treatment of Acute Renal Failure (ARF).
Antiva	UK	Start Up	Biotechnology Biopharmaceuticals	2010
Antiva, is a spin out business from Vantia Therapeutics (www.vantiatherapeutics.com)and alongside that business focuses on leading research into improving clinical treatments through development and commercialization of innovative medicines.
EUSA Pharma	UK	Expansion	Biotechnology Biopharmaceuticals	2007
EUSA Pharma (EUSA) is a fast growing, transatlantic specialty pharma company developing and commercializing a range of prescription products in pain, oncology and critical care. Currently, the Company has eight products on the market.
Itero Biopharmaceuticals	US	Early Stage	Biotechnology Biopharmaceuticals	2007
Itero is an early stage company focused on the development and commercialization of differentiated biosimilar and second generation protein products that serve niche markets.
Juvaris BioTherapeutics	US	Early Stage	Biotechnology Biopharmaceuticals	2009
Developing novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer.
Kalvista Pharmaceuticals	UK	Early Stage	Biotechnology Biopharmaceuticals	2011
Ophthalmology company developing Plasma Kallikrein inhibitors.
Link Medicine	US	Early Stage	Biotechnology Biopharmaceuticals	2008
Link Medicine is a clinical stage company spun out of Harvard University working on disease-modifying therapies for neurodegenerative diseases.
Logical Therapeutics	US	Start Up	Biotechnology Biopharmaceuticals	2007
Logical Therapeutics is a clinical stage drug development company with a focus on inflammation.
NeurogesX	US	Pipe	Biotechnology Biopharmaceuticals	2007
NeurogesX is developing novel topical products to relieve chronic pain and improve quality of life.
NKT Therapeutics, Inc	US	Early Stage	Biotechnology Biopharmaceuticals	2007
NKT Therapeutics is a biotechnology company focused on developing therapeutics based on a unique subset of immune cells called natural killer T ("NKT") cells.
Ophthotech	US	Seed	Biotechnology Biopharmaceuticals	2007
Ophthotech is dedicated to developing drugs for ophthalmic diseases with high unmet medical needs.
PanOptica	US	Seed	Biotechnology Biopharmaceuticals	2009
PanOptica is a start-up company dedicated to developing drugs for ophthalmic diseases with high unmet medical needs.
RespiVert	UK	Start Up	Biotechnology Biopharmaceuticals	2007
Sold to J&J in June 2010. RespiVert is a discovery company focused on Chronic obstructive pulmonary disease ('COPD') and severe asthma. The company's goal is to develop novel inhaled and intranasal drugs for respiratory disorders with high unmet medical need and high commercial potential based on novel insights on biology and chemistry.
Vantia Pharmaceuticals	UK	Start Up	Biotechnology Biopharmaceuticals	2008
Vantia Therapeutics is a leading research based healthcare company dedicated to improving clinical treatments through development & commercialisation of innovative medicines.
X2-Pharma	Germany	Seed	Biotechnology Biopharmaceuticals	2008
X2-Pharma is a biopharmaceutical company dedicated to the discovery and development of small molecule pharmaceuticals for the treatment of inflammatory diseases.
Arsanis	US	Early Stage	Biotechnology Biopharmaceuticals	2010
Development of Monoclonal Antibodies to target infectious diseases.
Autifony Therapeutics	UK	Early Stage	Biotechnology Biopharmaceuticals	2011
Focused on preclinical exploration and development of potential treatments for people with hearing disorders, including noise-induced hearing loss or tinnitus.
Bicycle Therapeutics	UK	Seed	Biotechnology Biopharmaceuticals	2009
Developing a platform technology that may enable the creation of a new generation of biotherapeutics.
Calchan Holdings	UK	Early Stage	Biotechnology Biopharmaceuticals	2011
Spin out from GSK. Focused on the development of novel analgesics with commercially attractive efficacy, responder-rate and side effect profiles
Catabasis Pharmaceuticals	US	Start Up	Biotechnology Biopharmaceuticals	2010
Developing therapeutics of the treatment of inflammatory and metabolic diseases.
Convergence Pharmaceuticals	UK	Early Stage	Biotechnology Biopharmaceuticals	2010
Spin out from GSK. Focused on the development of novel analgesics with commercially attractive efficacy, responder-rate and side effect profiles.
Cyterix Pharmaceuticals	US	Start Up	Biotechnology Biopharmaceuticals	2011
Cyterix is a start-up from UCSF and University of Dundee, focused on validating a broad platform to develop best in class anti-cancer agents.
Good Start Genetics	US	Early Stage	Biotechnology Biopharmaceuticals	2010
Pre-pregnancy genetic testing business
Imagen Biotech	US	Start Up	Biotechnology Biopharmaceuticals	2011
Developing drugs for dry age related macular degeneration (AMD)
Karus Therapeutics	UK	Early Stage	Biotechnology Biopharmaceuticals	2012
Karus Therapeutics is an emerging pharmaceutical company whose R&D activities are focused on the design and development of innovative, molecular-targeted, small molecule drugs to treat immune/inflammatory disorders and cancer.
Rempex Pharmaceuticals	US	Start Up	Biotechnology Biopharmaceuticals	2011
Developing best in class antibiotics and potentiators to address the growing threat of resistance to existing treatment of infections.
TopiVert	UK	Early Stage	Biotechnology Biopharmaceuticals	2011
Discovery and development of anti-inflammatory drugs for gastrointestinal and ophthalmic disorders.

⇧ Back to top